CONNECT WITH US
HealthTech

HealthTech

Genmab's stock rises on cancer data, while Iovance, Coherus tumble

Endpoints News logo

Published on

Add as a preferred source on Google
Genmab's stock rises on cancer data, while Iovance, Coherus tumble

Can­cer tri­al news drove a num­ber of stock moves in both di­rec­tions over the past 24 hours. Here’s a sum­ma­ry of key re­sults and their …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Backed by Amish and Men­non­ites, a new kind of gene ther­a­py com­pa­ny takes shape October 27, 2026

Den­mark's Gubra looks be­yond me­tab­o­lism, hopes for first port­fo­lio com­pa­ny this year October 27, 2026

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion

Up­dat­ed: Lil­ly beats rev­enue fore­casts, lift­ing full-year out­look for third straight quar­ter

Ex­clu­sive: Dren Bio nabs $350M for po­ten­tial 2027 launch of blood can­cer drug



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.